Company-wide Realignments - Additional Information (Details) $ in Millions	12 Months Ended
Dec. 31, 2020 USD ($)
Restructuring Cost And Reserve [Line Items]
Reversal of non-cash-stock-based compensation expense	$ 0.4
Restructuring costs	4.1
Tetraphase Pharmaceuticals, Inc.
Restructuring Cost And Reserve [Line Items]
Restructuring costs	$ 3.1

Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

+ Details

Name:	us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RestructuringCostAndReserveLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.

+ References

+ Details

Name:	us-gaap_RestructuringCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ljpc_TetraphasePharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: